Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 15/20 | 0.72 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.72 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.72 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9581590 | 1.00 | ABCC9 (0.72) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL9581581 | 1.00 | ABCC9 (0.72) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL9294493 | 0.87 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL9294494 | 0.87 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL9294498 | 0.87 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL9130144 | 0.87 | ABCC9 (0.71) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL9621189 | 0.87 | ABCC9 (0.71) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL9130150 | 0.87 | ABCC9 (0.71) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL9130135 | 0.87 | ABCC9 (0.71) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL9621182 | 0.87 | ABCC9 (0.71) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1612 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076961-A1 | COMBINATION TREATMENTS | Celex Oncology Innovations Limited (GB) | 2026-03-19 | — | — | US | claimed |
| US-12564573-B2 | Topical ocular delivery of cromakalim | QLARIS BIO, INC. (US) | 2026-03-03 | — | — | US | claimed |
| US-12564572-B2 | Topical ocular delivery of cromakalim | QLARIS BIO, INC. (US) | 2026-03-03 | — | — | US | claimed |
| US-20250387366-A1 | TOPICAL OCULAR DELIVERY OF CROMAKALIM | QLARIS BIO, INC. (US) | 2025-12-25 | — | — | US | claimed |
| WO-2025078664-A1 | TREATMENT OF METASTATIC OR INVASIVE BRAIN CANCER | Celex Oncology Innovations Limited (GB) | 2025-04-17 | — | — | WO | claimed |
| US-20250108035-A1 | TOPICAL OCULAR DELIVERY OF CROMAKALIM | QLARIS BIO, INC. (US) | 2025-04-03 | — | — | US | claimed |
| US-20250108002-A1 | TOPICAL OCULAR DELIVERY OF CROMAKALIM | QLARIS BIO, INC. (US) | 2025-04-03 | — | — | US | claimed |
| EP-4486338-A2 | TOPICAL OCULAR DELIVERY OF CROMAKALIM | Qlaris Bio, Inc. (US) | 2025-01-08 | — | — | EP | claimed |
| WO-2024098043-A2 | TOPICAL OCULAR DELIVERY OF CROMAKALIM | QLARIS BIO, INC. (US) | 2024-05-10 | — | — | WO | claimed |
| US-20220347172-A1 | COMBINATION TREATMENTS | Celex Oncology Innovations Limited (GB) | 2022-11-03 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20030139438-A1 | Diagnosis of the parkinsonian condition | MOTAC NEUROSCIENCE LIMITED (GB) | 2003-07-24 | — | — | US | claimed |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | PFIZER, INC. | 2003-03-06 | — | — | US | claimed |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | claimed |
| US-6436944-B1 | POTASSIUM CHANNEL OPENERS, AND SILDENAFIL, WHICH ELEVATES CGMP LEVELS | PFIZER INC. | 2002-08-20 | — | — | US | claimed |
| US-6395736-B1 | Compositions and methods for the treatment of anorectal disorders | CELLEGY PHARMACEUTICALS, INC. | 2002-05-28 | — | — | US | claimed |
| EP-1090644-A2 | Combination effective for the treatment of impotence comprising a potassium-channel-opener and a cGMP elevator | Pfizer Products Inc. (US) | 2001-04-11 | — | — | EP | claimed |
| WO-1994013272-A1 | USE OF POTASSIUM CHANNEL ACTIVATORS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF PAIN | SMITHKLINE BEECHAM PLC. (GB) | 1994-06-23 | — | — | WO | claimed |
| EP-0250077-B1 | PHARMACOLOGICALLY ACTIVE BENZOPYRANES | BEECHAM GROUP PLC (GB) | 1992-01-02 | — | — | EP | claimed |
| EP-0250077-A2 | Pharmacologically active benzopyranes | BEECHAM GROUP PLC (GB) | 1987-12-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387366-A1 | TOPICAL OCULAR DELIVERY OF CROMAKALIM | GK, PSEN1, NEFM | ABCC9 895/4885ABCC8 818/4885KCNJ11 301/4885 |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | GRIN3A, GRIN1, CHRNA10 | ABCC9 2860/4885ABCC8 3104/4885KCNJ11 365/4885 |
| US-12564572-B2 | Topical ocular delivery of cromakalim | PRKCZ, GK, PHYKPL | ABCC9 1943/4885ABCC8 1197/4885KCNJ11 1088/4885 |
| US-20250108002-A1 | TOPICAL OCULAR DELIVERY OF CROMAKALIM | PDE12, SYMPK, MYOC | ABCC9 1891/4885ABCC8 1831/4885KCNJ11 237/4885 |
| US-20260076961-A1 | COMBINATION TREATMENTS | SCNN1B, SCN2B, SCNN1A | ABCC9 255/4885ABCC8 314/4885KCNJ11 97/4885 |
| US-12564573-B2 | Topical ocular delivery of cromakalim | GK, PRKCZ, PHYKPL | ABCC9 2059/4885ABCC8 1046/4885KCNJ11 1324/4885 |
| US-20250108035-A1 | TOPICAL OCULAR DELIVERY OF CROMAKALIM | PDE12, SYMPK, MYOC | ABCC9 1891/4885ABCC8 1831/4885KCNJ11 237/4885 |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | CACNA1G, CACNA1F, CACNA1H | ABCC9 347/4885ABCC8 502/4885KCNJ11 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.